A systematic review and meta-analysis comparing the outcomes of open and robotic assisted radical cystectomy.

A systematic review and meta-analysis comparing the outcomes of open and robotic assisted radical cystectomy. Minerva Urol Nefrol. 2019 Oct 10;: Authors: Albisinni S, Veccia A, Aoun F, Diamand R, Esperto F, Porpiglia F, Roumeguère T, De Nunzio C Abstract INTRODUCTION: Robotic assisted radical cystectomy (RARC) is gaining popularity worldwide, although its enthusiastic implementation is supported mainly by retrospective studies. Aim of this review is to compare the outcomes of RARC and open radical cystectomy (ORC) in the setting of randomized controlled trials (RCTs). EVIDENCE ACQUISITION: Three search engines (PubMed, Embase®, and Web of Science) were queried up to January 1, 2019. Studies selections followed The Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) Statement to find studies regarding patients with clinically localized muscle invasive and high risk non muscle invasive bladder cancer who underwent RARC or ORC to evaluate surgical, pathological, and oncological outcomes. The statistical analysis was performed with RevMan 5.3. EVIDENCE SYNTHESIS: Five randomized controlled trial were identified. We found RARC group to be not associated to neoadjuvant chemotherapy (OR: 0.67; 95%CI: 0.46, 0.98; p=0.04). ORC had shorter operative time (OT) (WMD: 95.14 minutes; 95%CI: 50.59, 139.68; p
Source: Minerva Urologica e Nefrologica - Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research

Related Links:

Publication date: Available online 13 November 2019Source: Artificial Intelligence in MedicineAuthor(s): Ivan Lorencin, Nikola Anđelić, Josip Španjol, Zlatan CarAbstractIn this paper, the urinary bladder cancer diagnostic method which is based on Multi-Layer Perceptron and Laplacian edge detector is presented. The aim of this paper is to investigate the implementation possibility of a simpler method (Multi-Layer Perceptron) alongside commonly used methods, such as Deep Learning Convolutional Neural Networks, for the urinary bladder cancer detection. The dataset used for this research consisted of 1997 images of bl...
Source: Artificial Intelligence in Medicine - Category: Bioinformatics Source Type: research
Response classification after neoadjuvant chemotherapy in muscle-invasive bladder carcinoma is based on the TNM stage at radical cystectomy. We recently showed that histopathologic tumor regression grades (TRGs) add prognostic information to TNM. Our aim was to validate the prognostic significance of TRG in muscle-invasive bladder cancer in a multicenter setting. We enrolled 389 patients who underwent cisplatin-based chemotherapy before radical cystectomy in 8 centers between 2010 and 2016. Median follow-up was 2.2 years. TRG was determined in radical cystectomy specimens by local pathologists. Central pathology review was...
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research
A combination of anthrax and a growth factor found on the surface of bladder cancer cells allowed Purdue University researchers to target and kill tumors with unprecedented speed.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
RAS protein activator like 2 (RASAL2) belongs to the RAS GTPase-activating protein family and plays an important role in several cancers, including ovarian cancer, nasopharyngeal carcinoma, malignant astrocytoma, renal cell carcinoma, bladder cancer, colorectal cancer, liver cancer, triple-negative breast cancer, lung adenocarcinoma, and pancreatic ductal adenocarcinoma. Traditionally, RASAL2 has been regarded as a tumor suppressor but recent studies have found that it is an oncogene in specific types of cancer, such as colorectal cancer, liver cancer, triple-negative breast cancer, triple-negative/estrogen receptor-negati...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
The objective of the study was to compare perioperative and mid-term oncologic outcomes of RARC versus ORC in a real-life cohort of patients treated by surgeons starting their experience with RARC.Materials and methodsData were prospectively collected from consecutive patients undergoing RARC and ORC at five referral Centers between 2010 and 2016 by five surgeons (one per center) with no prior experience in RARC. Patients with high-risk non-muscle-invasive or organ-confined muscle-invasive (T2N0M0) bladder cancer were considered for RARC. The main study endpoints were perioperative outcomes, postoperative surgical complica...
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
(Purdue University) Researchers at Purdue University have come up with a way to combine the anthrax toxin with a growth factor to kill bladder cancer cells and tumors.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
ConclusionsGal-9+TAMs predicted OS and RFS and response to ACT in MIBC patients. High Gal-9+TAMs were associated with a pro-tumor immune contexture concomitant with T cell exhaustion.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Conclusions The TT genotype of XPC rs2228000 may be linked to an increased risk of bladder and breast cancer, whereas the CT genotype is likely to be associated with reduced susceptibility to gastric cancer in the Chinese population. PMID: 31710080 [PubMed - as supplied by publisher]
Source: Bioscience Reports - Category: Biomedical Science Authors: Tags: Biosci Rep Source Type: research
Abstract PURPOSE: To characterize immune cell expression among patients with Non-Muscle Invasive Bladder Cancer (NMIBC) treated with BCG. EXPERIMENTAL DESIGN: Patients with NMIBC treated with intravesical BCG (2008-2015) were identified, and a TMA was constructed using paired pre and post-BCG bladder samples. Immunohistochemistry was performed for CD8, CD4, FoxP3, PD-L1 (SP-142 and 22C3) and PD-1. A full slide review of PD-L1+ staining tumors was performed to characterize PD-L1 and CD8 co-localization. RNAseq was performed on cored tumors from available specimens. We compared immune cell populations between B...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
ConclusionsThe updated PURE-01 results confirm the activity of neoadjuvant pembrolizumab in MIBC. Patients with SCC and LEL features may be suitable for neoadjuvant immunotherapy trials. CPS and TMB are the key response predictors irrespective of the histological subtypes.Patient summaryIn the PURE-01 study, we have preliminarily evaluated the activity of neoadjuvant pembrolizumab in patients with predominant variant histology (VH). Of these patients, those harboring squamous-cell carcinoma or a lymphoepithelioma-like variant feature had major, although preliminary, pathological responses compared with those with other pre...
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Minimally Invasive Surgery | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Science | Statistics | Study | Urology & Nephrology